Status:
UNKNOWN
A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Cancer
Solid Tumors
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this observational study in France is to evaluate changes in satisfaction with care in participants with solid tumors who transitioned from receiving immunotherapy treatment in the hosp...
Eligibility Criteria
Inclusion
- Male or female ≥ 18 years old
- Participants whose oncology specialist has already initiated treatment with immune checkpoint inhibitors (ICIs) in the outpatient hospital setting for an advanced solid tumor (as monotherapy or in combination) or as adjuvant therapy, in an indication approved and reimbursed in France
- Participants whose oncology specialist has independently of the study defined their eligibility for hospital at home (HAH) before contacting the HAH unit for final admission
- Participants who provide oral informed consent to participate in the study
Exclusion
- Participants who have expressed an opposition to their data collection
- Participants under guardianship
- Participants taking part in an interventional study for cancer treatment with at least one ICI as an investigational drug
Key Trial Info
Start Date :
August 29 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06163053
Start Date
August 29 2023
End Date
February 28 2025
Last Update
December 8 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Metropole Savoie
Chambéry, France, 73011
2
CH Francois Quesnay
Mantes-la-Jolie, France, 78200
3
CH de Pau
Pau, France, 64046